Asthika Goonewardene
Stock Analyst
(n/a)
# 4,648
Out of 4,648 analysts
81
Total ratings
n/a
Success rate
n/a
Average return
Main Sectors:
Top Industries:
Stocks Rated by Asthika Goonewardene
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EXEL Exelixis | Maintains: Buy | $33 → $38 | $34.12 | +11.37% | 6 | Oct 30, 2024 | |
| IGMS IGM Biosciences | Downgrades: Hold | $24 → $12 | $16.22 | -26.02% | 7 | Oct 1, 2024 | |
| GMAB Genmab | Maintains: Buy | $53 → $50 | $22.56 | +121.63% | 13 | Sep 9, 2024 | |
| STRO Sutro Biopharma | Maintains: Buy | $18 → $15 | $3.55 | +322.54% | 6 | Aug 16, 2024 | |
| ALLO Allogene Therapeutics | Reiterates: Buy | $17 → $14 | $2.72 | +414.71% | 6 | Aug 9, 2024 | |
| RCUS Arcus Biosciences | Maintains: Buy | $50 → $44 | $15.50 | +183.87% | 1 | Jun 24, 2024 | |
| ACLX Arcellx | Maintains: Buy | $87 | $86.17 | +0.96% | 4 | Jun 18, 2024 | |
| LEGN Legend Biotech | Initiates: Buy | $88 | $44.36 | +98.38% | 1 | Jun 17, 2024 | |
| MRUS Merus | Maintains: Buy | $69 → $88 | $50.30 | +74.95% | 2 | Jun 4, 2024 | |
| CGEN Compugen | Maintains: Buy | $5 → $4 | $1.71 | +133.92% | 5 | May 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 | $2.21 | +759.73% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $34 → $32 | $20.37 | +57.09% | 2 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $26 | $11.19 | +132.35% | 5 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $9 | $1.82 | +394.51% | 3 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $3.84 | +941.67% | 4 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $27 | $1.25 | +2,060.00% | 2 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 → $9 | $3.50 | +157.14% | 3 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Hold | $120 | $28.78 | +316.96% | 1 | Apr 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Hold | $100 → $60 | $1.44 | +4,066.67% | 3 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $1.33 | +1,027.82% | 4 | Aug 23, 2022 |
Exelixis
Oct 30, 2024
Maintains: Buy
Price Target: $33 → $38
Current: $34.12
Upside: +11.37%
IGM Biosciences
Oct 1, 2024
Downgrades: Hold
Price Target: $24 → $12
Current: $16.22
Upside: -26.02%
Genmab
Sep 9, 2024
Maintains: Buy
Price Target: $53 → $50
Current: $22.56
Upside: +121.63%
Sutro Biopharma
Aug 16, 2024
Maintains: Buy
Price Target: $18 → $15
Current: $3.55
Upside: +322.54%
Allogene Therapeutics
Aug 9, 2024
Reiterates: Buy
Price Target: $17 → $14
Current: $2.72
Upside: +414.71%
Arcus Biosciences
Jun 24, 2024
Maintains: Buy
Price Target: $50 → $44
Current: $15.50
Upside: +183.87%
Arcellx
Jun 18, 2024
Maintains: Buy
Price Target: $87
Current: $86.17
Upside: +0.96%
Legend Biotech
Jun 17, 2024
Initiates: Buy
Price Target: $88
Current: $44.36
Upside: +98.38%
Merus
Jun 4, 2024
Maintains: Buy
Price Target: $69 → $88
Current: $50.30
Upside: +74.95%
Compugen
May 21, 2024
Maintains: Buy
Price Target: $5 → $4
Current: $1.71
Upside: +133.92%
May 16, 2024
Maintains: Buy
Price Target: $19
Current: $2.21
Upside: +759.73%
May 16, 2024
Reiterates: Buy
Price Target: $34 → $32
Current: $20.37
Upside: +57.09%
Mar 7, 2024
Maintains: Buy
Price Target: $17 → $26
Current: $11.19
Upside: +132.35%
Feb 29, 2024
Upgrades: Buy
Price Target: $9
Current: $1.82
Upside: +394.51%
Sep 6, 2023
Reiterates: Buy
Price Target: $40
Current: $3.84
Upside: +941.67%
Sep 6, 2023
Reiterates: Buy
Price Target: $27
Current: $1.25
Upside: +2,060.00%
Aug 17, 2023
Maintains: Buy
Price Target: $6 → $9
Current: $3.50
Upside: +157.14%
Apr 5, 2023
Reinstates: Hold
Price Target: $120
Current: $28.78
Upside: +316.96%
Aug 23, 2022
Maintains: Hold
Price Target: $100 → $60
Current: $1.44
Upside: +4,066.67%
Aug 23, 2022
Maintains: Buy
Price Target: $19 → $15
Current: $1.33
Upside: +1,027.82%